Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

Trial Profile

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Gallium 68 PSMA (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 21 Jun 2017 New trial record
    • 06 Jun 2017 Results assessing incidence of intrathoracic metastases, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Status changed from recruiting to active, no longer recruiting, according to the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top